A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

Clinical trial NCT04333706 · RECRUITING

Trial details

NCT number: NCT04333706
Sponsor: University of Southern California
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Metastatic Triple Negative Cancer Disseminated Tumor Cell

Start date: 2020-09-26
Primary completion: 2026-11-03
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.